logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

mCRC: adding erlotinib to bevacizumab prolongs PFS, OS

Individual trials showed mixed results, but the meta-analysis suggests efficacy.